J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers

Potential For Post-Tagrisso Therapy Niche

 
• By Alaric DeArment
  
lung illustration
J&J gets FDA speedy FDA approval for Rybrevant in non-small cell lung cancer with EGFR exon 20 insertion mutation • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer